The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending booster shots.

The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about $29 million upfront.

The president’s executive order promising to lower pharmaceutical prices includes support for a fix long sought by the ...

The advisory committee, which met Tuesday for the first time since Robert F. Kennedy Jr. was sworn in as health secretary, ...

Two studies published in Nature found stem-cell derived products can not only be safely transplanted into the brain, but also ...